Clinical Trial Update: Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing CD8+-enriched autologous lymphocyte transfer after non-myeloablative chemotherapy to high-dose Aldesleukin in melanoma pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• CD8+-enriched short-term cultured anti-tumor autologous lymphocytes

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Skin Cancer, Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-06-03